Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Stock Report

Market Cap: US$107.8b

Vertex Pharmaceuticals Management

Management criteria checks 4/4

Vertex Pharmaceuticals' CEO is Reshma Kewalramani, appointed in Apr 2020, has a tenure of 3.92 years. total yearly compensation is $15.86M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $56.97M. The average tenure of the management team and the board of directors is 4.4 years and 5.1 years respectively.

Key information

Reshma Kewalramani

Chief executive officer

US$15.9m

Total compensation

CEO salary percentage8.8%
CEO tenure3.9yrs
CEO ownership0.05%
Management average tenure4.4yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02
Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

Sep 19

Vertex wins FDA label expansion for cystic fibrosis drug to add younger children

Sep 02

Vertex: CF Monopoly, Looking To Expand

Aug 05

Vertex to run late-stage studies for pain therapy in 4Q 2022

Jul 22

CEO Compensation Analysis

How has Reshma Kewalramani's remuneration changed compared to Vertex Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$4b

Sep 30 2023n/an/a

US$3b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$3b

Dec 31 2022US$16mUS$1m

US$3b

Sep 30 2022n/an/a

US$3b

Jun 30 2022n/an/a

US$3b

Mar 31 2022n/an/a

US$2b

Dec 31 2021US$15mUS$1m

US$2b

Sep 30 2021n/an/a

US$2b

Jun 30 2021n/an/a

US$2b

Mar 31 2021n/an/a

US$3b

Dec 31 2020US$9mUS$1m

US$3b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$702k

US$1b

Compensation vs Market: Reshma's total compensation ($USD15.86M) is about average for companies of similar size in the US market ($USD12.45M).

Compensation vs Earnings: Reshma's compensation has been consistent with company performance over the past year.


CEO

Reshma Kewalramani (49 yo)

3.9yrs

Tenure

US$15,864,497

Compensation

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She has been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Leiden
Executive Chairman14.7yrsUS$8.59m0.0055%
$ 5.9m
Reshma Kewalramani
CEO, President & Director3.9yrsUS$15.86m0.053%
$ 57.0m
Charles Wagner
Executive VP & CFO4.9yrsUS$5.81m0.021%
$ 22.4m
Stuart Arbuckle
Executive VP & COO2.7yrsUS$15.00m0.019%
$ 20.8m
David Altshuler
Executive VP & Chief Scientific Officer9.2yrsUS$6.53m0.010%
$ 10.8m
Kristen Ambrose
Senior VP & Chief Accounting Officer2.8yrsno data0.0031%
$ 3.3m
Mike Tirozzi
SVP and Chief Information & Data Officer5.2yrsno datano data
Susie Lisa
Senior Vice President of Investor Relations1.5yrsno datano data
Jonathan Biller
Executive VP & Chief Legal Officer1.5yrsno data0.0071%
$ 7.6m
Nina Devlin
Senior VP & Chief Communications Officer5.2yrsno datano data
Stephanie Franklin
Senior VP & Chief Human Resources Officer6.6yrsno datano data
Amit Sachdev
Executive VP & Chief Patient and External Affairs Officer16.7yrsUS$6.20m0.024%
$ 26.2m

4.4yrs

Average Tenure

56yo

Average Age

Experienced Management: VRTX's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Leiden
Executive Chairman14.7yrsUS$8.59m0.0055%
$ 5.9m
Reshma Kewalramani
CEO, President & Director4.1yrsUS$15.86m0.053%
$ 57.0m
Bruce Sachs
Lead Independent Director26.2yrsUS$600.02k0.015%
$ 16.7m
Terrence Kearney
Independent Director12.8yrsUS$542.73k0.0025%
$ 2.7m
Alan Garber
Independent Director6.8yrsUS$525.02k0.0023%
$ 2.5m
Lloyd Carney
Independent Director5.1yrsUS$552.67k0.0016%
$ 1.7m
Sangeeta Bhatia
Independent Director8.8yrsUS$550.17k0.0011%
$ 1.1m
Michel Lagarde
Independent Directorless than a yearno datano data
Diana McKenzie
Independent Director3.8yrsUS$538.17k0.00064%
$ 689.9k
Suketu Upadhyay
Independent Director1.8yrsUS$469.59k0%
$ 0
Nancy Thornberry
Independent Directorless than a yearno datano data

5.1yrs

Average Tenure

61yo

Average Age

Experienced Board: VRTX's board of directors are considered experienced (5.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.